Mahboob Aslam, MD
Addiction Medicine · Rocky Hill, CTNPI 1801094479
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (58.0%), travel and lodging and education — rather than concentrated in one kind of arrangement. Neuronetics, Inc. accounts for 65.7% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2022 at $1,275 and has fallen 92.1% since, to $101 in 2025.
Across 36 payments — averaging $53.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neuronetics, Inc.$1K
- AbbVie$421
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$86
- Alkermes, Inc.$53
- Otsuka America Pharmaceutical, Inc.$43
- Lundbeck LLC$28
- plus $32 from 2 others
What the payments were for
- Travel & lodging$76039%
- Food & beverage$1,12558%
- Education$533%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neuronetics, Inc. | 2 | $1,275 |
| AbbVie | 21 | $421 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $86 |
| Alkermes, Inc. | 4 | $53 |
| Otsuka America Pharmaceutical, Inc. | 2 | $43 |
| Lundbeck LLC | 1 | $28 |
| Vanda Pharmaceuticals Inc. | 1 | $18 |
| Braeburn Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NEUROSTAR TMS THERAPY SYSTEM$1,275
- VRAYLAR$125
How this compares
$1,939 in reported general payments places this provider in the 85th percentile of 28 addiction medicine providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 661 | $121,248 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 88 | $60,534 |
| VraylarCariprazine Hcl | 31 | $35,343 |
| ZubsolvBuprenorphine Hcl/Naloxone Hcl | 12 | $3,691 |
| Asenapine Maleate | 16 | $2,985 |
| Divalproex Sodium ErDivalproex Sodium | 27 | $2,486 |
| Clonazepam | 230 | $1,769 |
| Duloxetine Hcl | 159 | $1,461 |
| Buprenorphine Hcl | 16 | $1,431 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 21 | $923 |
| Doxepin Hcl | 62 | $871 |
| Tizanidine Hcl | 13 | $782 |
| Bupropion XlBupropion Hcl | 52 | $568 |
| Gabapentin | 61 | $563 |
| Quetiapine Fumarate | 55 | $459 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $421 | $35,34331 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 28 addiction medicine providers in Connecticut.
Other addiction medicine in Rocky Hill
- Edith HerganRocky Hill$1K
- Jay BensonRocky Hill$393
- Jenna ButnerNew Haven$27K
- Ayaz MadraswallaPutnam$14K
- Neal LakritzEnfield$3K
- Thomas DefantiNorth Stonington$1K
- John AntonucciNewington$1K
- Brian KarsifNew Haven$528
- Sijie WangFarmington$387
- Katherine GriecoHartford$376
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.